Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
Status:
Completed
Trial end date:
2020-02-26
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and
tolerability of Glucagon RTU when administered to subjects with a history of bariatric
surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be
randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research
center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will
be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week
Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a
subject's last dose of study drug.